The problem with Her2-low testing
Daiichi and Astrazeneca want to extend Enhertu’s reach. But it’s hard to know whether the tests to identify the right patients actually work.
Gossamer could put pressure on Merck
The pharma giant leads the pulmonary arterial hypertension pipeline, but other potentially disease-modifying treatments are in the works.
Abeona takes on Amryt – and more importantly, Krystal
Three new epidermolysis bullosa therapies are approaching the US, and expectations vary wildly.
Looking for winners in geographic atrophy
NGM’s NGM621 now looks like a dead end, but there are plenty of others hoping for a piece of this market, including Roche and Lineage.
Cancer “vaccines” enter the neoantigen stage
Attempts to raise a personalised immune response against neoantigens have attracted big pharma interest, most recently from Merck & Co.
PCSK9 pipeline shows signs of saturation
Astrazeneca and Ionis’s discontinuation could herald a nervous time for others in this space.
Horizon still has a mountain to climb
But positive mid-stage Sjögren’s data raise hopes for others still plugging away at anti-CD40 assets.
Can Kalvista make HAE after Pharvaris’s misstep?
A clinical hold for Pharvaris raises questions about the group’s approach, and could leave the door open for its acute rival.
Cytokine players keep the faith
The demise of Nektar’s bempegaldesleukin has not stemmed the tidal wave of companies developing IL-2 and IL-15 therapies.
